Coleman Mark sold $160K of AXSM
Coleman Mark sold 643 shares of Axsome Therapeutics, Inc. (AXSM) at $249.00 ($0.16M total) on 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale under a 10b5-1 plan is generally considered lower-signal than discretionary selling, so the market impact is typically limited.
Market read
Primarily a sentiment datapoint; not a new fundamental development for AXSM.
What to watch
Watch for follow-on insider activity (additional sales/buys) or any concurrent company-specific news; a single small sale often has limited predictive value.
Background
The article reports an SEC Form 4 insider transaction for Axsome Therapeutics, Inc. (AXSM).
Ticker impact
Director Coleman Mark sold 643 shares of Axsome Therapeutics on 2026-06-10 at $249/share under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear read-across to the broader biotech sector from a single director 10b5-1 sale.
None.
None.
Counterpoint
Because the sale is pre-arranged, it may reflect scheduled liquidity rather than bearish views; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerAxsome Therapeutics, Inc.
Subject of the Form 4 insider transaction (AXSM).
- insiderColeman Mark
Director who sold 643 shares on 2026-06-10 under a pre-arranged 10b5-1 plan.
